Screener
BioCryst Pharmaceuticals BCRX Acquisitions
Acquisitions at other companies
Other financials
Where this comes from
Reported directly by BioCryst Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired.
The source filing: BioCryst Pharmaceuticals’s 10-Q, filed May 6, 2026.
- Filed
- May 6, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-031238
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Acquisitions of property and equipment | (403) | (143) |
| Purchases of investments | — | (48,762) |
| Sales and maturities of investments | 221,235 | 76,000 |
| Acquisition of Astria Therapeutics, Inc., net of cash acquired | (489,480) | — |
| Net cash (used in) provided by investing activities | (268,648) | 27,095 |
| Cash flows from financing activities: | ||
| Net proceeds from common stock issued under stock-based compensation plans | 19,479 | 2,390 |
| Withholding taxes paid on stock-based awards | (1,187) | (1,351) |
Item 1. Financial Statements (Unaudited):
FAQ
- What is BioCryst Pharmaceuticals's acquisitions?
- BioCryst Pharmaceuticals (BCRX) reported acquisitions of $489.48M in Q1 2026.
- What does acquisitions mean?
- Cash paid for business acquisitions net of cash acquired in the target company — the primary M&A cash flow line.
Ask your AI about BioCryst Pharmaceuticals's acquisitions.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude